Updated
Updated · POLITICO Europe · Aug 10
UK Regulator Approves Eli Lilly's Foundayo Pill for 2 Uses, a First European License
Updated
Updated · POLITICO Europe · Aug 10

UK Regulator Approves Eli Lilly's Foundayo Pill for 2 Uses, a First European License

3 articles · Updated · POLITICO Europe · Aug 10

Summary

  • Britain's MHRA cleared Foundayo on Monday for both weight management and type 2 diabetes, giving Eli Lilly its first European approval for the oral GLP-1 drug.
  • The decision puts the UK ahead of the EU, where a ruling on orforglipron is not expected until next year.
  • Foundayo is Lilly's first pill in the fast-growing GLP-1 class, extending a franchise that already includes injectable Mounjaro.
  • Demand for GLP-1 treatments has surged as celebrity and influencer backing helped push obesity drugs into the mainstream.

Insights

Could a simple daily pill finally end the era of painful weight-loss injections and revolutionize obesity treatment forever?
What hidden financial costs await patients swapping their weight-loss jabs for Britain's newly approved appetite-suppressing tablet?
Will this convenient new weight-loss pill truly conquer obesity, or simply trap millions in a lifelong pharmaceutical dependency?